Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key
hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective …

Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

Proteins are manufactured by ribosomes—macromolecular complexes of protein and RNA
molecules that are assembled within major nuclear compartments called nucleoli,. Existing …

Features of the cancer epigenome distinguish cancers from their respective cell of origin and
establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition …

Drugs targeting the cell cycle–regulatory cyclin-dependent kinase (CDK) 4 and 6 have been
approved for the treatment of hormone receptor–positive breast cancer, and inhibitors …

Abstract Purpose: Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and
potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have …

Mitophagy is a type of selective macroautophagy/autophagy that degrades dysfunctional or
excessive mitochondria. Regulation of this process is critical for maintaining cellular …

Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …

BRD4 is well known for its role in super-enhancer organization and transcription activation
of several prominent oncogenes including c-MYC and BCL2. As such, BRD4 inhibitors are …